DR MELLOR IN THE NEWS
Dr Mark Mellor regularly contributes to media discussion on obesity, GLP-1 and other obesity medications, cardiometabolic health, weight bias and stigma, and equitable access to evidence-based obesity care.
ABC NEWS | JANUARY 2026
Weight loss drug Wegovy to be subsidised for Australians with severe obesity. Dr Mellor discusses proposed PBS access to semaglutide for obesity, cardiovascular risk and the importance of prioritising treatment for people at greatest health risk.
SBS NEWS | 2026
Semaglutide medications recommended for obesity and heart disease. Dr Mellor discusses the close relationship between obesity and cardiovascular disease following the release of the Heart Foundation’s clinical consensus statement on obesity and heart health.
THE GUARDIAN | JULY 2026
Millions of people are losing weight using GLP-1s. How do the drugs affect their love lives? Dr Mellor provides a clinical perspective on the psychological and social changes that can accompany significant weight loss and treatment with GLP-1 medications.
MEDICAL REPUBLIC | MAY 2026
Finally, national consensus on obesity and cardiovascular disease. Dr Mellor discusses changing perceptions of obesity, weight stigma and the importance of recognising obesity as a chronic disease requiring evidence-based, long-term care.
MEDICAL FORUM | JULY 2026
Safety warning: GLP-1s linked to serious eye disorder. Dr Mellor discusses emerging safety information relating to GLP-1 therapies and the importance of balancing uncommon risks against their established health benefits.
AUSDOC | JULY 2025
GPs meet health officials in campaign to fund obesity drugs on PBS. Dr Mellor discusses national advocacy to improve equitable access to evidence-based obesity pharmacotherapy through the Pharmaceutical Benefits Scheme.
HEART FOUNDATION | STORIES FROM THE HEART
Shaping the Future of Obesity and Heart Disease Care.
Dr Mellor joins leading Australian clinicians and researchers to discuss obesity, cardiovascular disease and the development of Australia’s clinical consensus statement on obesity and heart health.
MEDIA & SPEAKING ENQUIRIES
Dr Mellor is available for expert media commentary, interviews and professional speaking engagements relating to obesity and metabolic health, obesity pharmacotherapy, GLP-1 medicines, cardiovascular risk, weight stigma and contemporary models of obesity care.
For media or speaking enquiries, please email or call the clinic.